Dr David Tougeron is a professor of gastroenterology at Poitiers University Hospital, France. His clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer. Dr Tougeron has participated in more than 40 clinical trials in digestive oncology and has co-authored more than 50 articles, editorials and book chapters. After a Ph.D. in immune response in colorectal cancer, Dr Tougeron completed a postdoctoral position at the Mayo Clinic, U.S., in colorectal cancer chemosensitivity. His research is currently focussing on colorectal cancer, particularly colorectal cancer with microsatellite instability and predictive biomarkers of response to targeted therapies. He presently holds professional positions in different organisations, notably the Fédération Francophone de Cancérologie Digestive (FFCD).

Prof. David Tougeron has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, BMS, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi and Servier.